(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
5 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 15.42%
Live Chart Being Loaded With Signals
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States...
Stats | |
---|---|
Dagens volum | 129 518 |
Gjennomsnittsvolum | 5.50M |
Markedsverdi | 12.69M |
EPS | $0 ( 2024-03-28 ) |
Neste inntjeningsdato | ( $-0.170 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.190 |
ATR14 | $0.00900 (1.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-31 | Cittadine Andrew | Sell | 8 952 | Restricted Stock Units |
2024-03-31 | Cittadine Andrew | Buy | 8 952 | Common Stock |
2024-03-31 | Cittadine Andrew | Sell | 3 098 | Common Stock |
2024-03-31 | Tsuchimoto Kim R | Sell | 9 956 | Restricted Stock Units |
2024-03-31 | Tsuchimoto Kim R | Buy | 9 956 | Common Stock |
INSIDER POWER |
---|
36.92 |
Last 100 transactions |
Buy: 1 127 208 | Sell: 341 037 |
Volum Korrelasjon
Monopar Therapeutics Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
LRMR | 0.907 |
NAKD | 0.856 |
SGMO | 0.85 |
CFLT | 0.849 |
HCSG | 0.827 |
EQ | 0.823 |
TUEM | 0.819 |
CSII | 0.819 |
MEDP | 0.815 |
SRRA | 0.814 |
10 Mest negative korrelasjoner | |
---|---|
BLKB | -0.827 |
LIZI | -0.825 |
LMPX | -0.825 |
SSRM | -0.81 |
SGLB | -0.809 |
EGAN | -0.806 |
RMRM | -0.801 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Monopar Therapeutics Inc Korrelasjon - Valuta/Råvare
Monopar Therapeutics Inc Økonomi
Annual | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $0 (0.00 %) |
EPS: | $-0.610 |
FY | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $0 (0.00 %) |
EPS: | $-0.610 |
FY | 2022 |
Omsetning: | $0 |
Bruttogevinst: | $0 (0.00 %) |
EPS: | $-0.830 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-0.730 |
Financial Reports:
No articles found.
Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.